MedBiome’s founders reported in Nature Comms. on the development of 96-well plate approach that maintains functional and compositional profiles of individual gut microbiomes. They demonstrated strong correlation between in vitro and in vivo microbiome responses to drugs.
Looking forward to multiple partnership meetings at Bio International in Philadelphia.
Dr. Daniel Figeys, co-founder of MedBiome, published a new set of guidelines to perform and analyze metaproteomics studies of human microbiomes.
MedBiome is pleased to announce its participation in the MaRS HealthKick Invest 2019 event.
Dr. Daniel Figeys, Dr. Alain Stintzi and their teams at the University of Ottawa are further developing the RapidAIM platform. The team is currently developing commercial applications, which include a fully automated, high-throughput prototype of the RapidAIM platform.
Dr. Alain Stintzi and Dr. Daniel Figeys were at Bio Europe in Copenhagen in November 2018. They presented the RapidAIM platform to rapidly study the effects of drugs and other compounds on individual human microbiome. They also presented their therapeutic development for pediatric IBD.
MedBiome’s founders published an article on the associations between microbiome and intestinal extracellular vesicle proteins in pediatric inflammatory bowel disease. see PubMed link
